Interleukin 2 News and Research

RSS

SARS-CoV-2 can cause sustained biochemical dysregulation that results in long-COVID

This state has come to be known as long-COVID, and in a paper recently uploaded to the preprint server medRxiv* by Simjanoska et al. (September 7th, 2021) the biochemical parameters of long-COVID patients with prior mild, moderate, or severe COVID-19 that resulted in hospitalization are tracked in detail, finding a characteristically dysregulated immune and inflammatory response in the most seriously ill.

15 Sep 2021

Flu shots and COVID-19 immunity

A new paper finds that the influenza vaccine may influence both the response to and incidence of infection by the SARS-CoV-2.

14 Sep 2021

Researchers explore whether cocoa supplementation can reduce aging

Whether consuming cocoa, known to be packed with powerful antioxidants that protect our cells from damage, helps us age better, is a question scientists want to definitively answer.

14 Sep 2021

Immune-mediated inflammatory disease may increase risk of severe COVID-19 outcomes

Researchers in the UK have conducted a large population-based study showing that people with immune-mediated inflammatory diseases (IMIDs) appear to be at an increased risk of serious outcomes from coronavirus disease 2019 (COVID-19).

14 Sep 2021

Metabolic and immune markers as tools for risk stratification and monitoring in COVID-19

In a new study posted to the medRxiv* server scientists from Weil Cornell University and Stony Brook University in New York attempted to identify the metabolic and immune markers associated with severe COVID-19 disease using high-throughput targeted nuclear magnetic resonance (NMR) spectroscopy and high-dimensional flow cytometry. This will facilitate risk stratification, monitoring, and therapeutic interventions in COVID-19 patients.

14 Sep 2021

A review of mesenchymal stem cell therapy for severe COVID-19

Researchers find that MSC treatment is highly tolerated and effective in reducing lung damage in COVID-19 patients and improving their chances of recovery.

13 Sep 2021

Cellular program could turn T cells into effective cancer killers

Cancer-fighting immune cells in patients with lung cancer whose tumors do not respond to immunotherapies appear to be running on a different "program" that makes them less effective than immune cells in patients whose cancers respond to these immune treatments, suggests a new study led by researchers at the Johns Hopkins Kimmel Cancer Center Bloomberg~Kimmel Institute for Cancer Immunotherapy.

9 Sep 2021

COVID-19 vaccine antibodies inversely related to BMI in obese men, but not women

A new study discusses the role of obesity in COVID-19 and its role in antibody-mediated immune responses to the COVID-19 vaccine.

7 Sep 2021

Activated mast cell disorders potentially linked to SARS-CoV-2 immunity

An intriguing new study reports a year-long study in patients with cMCADs from all over France.

7 Sep 2021

Implications of persistent SARS-CoV-2 infection in patients with lymphoid malignancies

In a recent study, scientists attempt to understand persistent COVID-19 and its implications in patients with hematologic malignancies.

6 Sep 2021

Research uncovers test to identify iMCD patients with superior response to FDA-approved treatment

New research has uncovered a precision medicine test using blood proteins to identify a novel patient subgroup of idiopathic multicentric Castleman disease (iMCD), a rare blood disorder, who are more likely to respond to siltuximab, the only FDA approved treatment for the disease.

2 Sep 2021

Newly discovered cell type makes survivors of sepsis more vulnerable to infections

Sepsis is the leading cause of death in Brazil's intensive care units (ICUs). Among patients who progress to the severe form of the disease, 40% die, and the survivors often suffer from cardiovascular and neurological complications, as well as a significant decline in immunity lasting for years after they are discharged from hospital.

2 Sep 2021

Implanted cells deliver a biologic drug in response to inflammation in rheumatoid arthritis

With a goal of developing rheumatoid arthritis therapies with minimal side effects, researchers at Washington University School of Medicine in St. Louis have genetically engineered cells that, when implanted in mice, will deliver a biologic drug in response to inflammation.

1 Sep 2021

Attenuated virulence and protective immunity in SARS-CoV-2 with a mutation in the S1/S2 cleavage site

A new study published in mBio investigates the impact of the furin cleavage site on viral growth and pathogenesis.

31 Aug 2021

DNMT2/TRDMT1 gene knockout may potentiate adverse effects related to drug-induced senescence

Aging-US published "The lack of functional DNMT2/TRDMT1 gene modulates cancer cell responses during drug-induced senescence" which reported that cellular senescence may be a side effect of chemotherapy and other anti-cancer treatments that may promote inflammation and paracrine secondary senescence in healthy tissues.

31 Aug 2021

The impact of mild SARS-CoV-2 infection on maternal-fetal immunity

Recently, a new study published on the pre-print server bioRxiv* examined the effect that maternal asymptomatic COVID-19 had on decidual and peripheral immune cells during the later stage of pregnancy.

30 Aug 2021

Polymeric and lipid nanoparticles in self-amplifying RNA vaccines result in higher protein expression and immunogenicity

Self-amplifying RNA (saRNA) is an advanced platform for nucleic acid vaccine development. The backbone is typically derived from an alphaviral genome and encodes a gene of interest (GOI) and a viral replicase that can amplify the genomic and subgenomic RNA.

30 Aug 2021

Next-gen COVID vaccine to make persistent neutralizing antibodies

Presently, there is a need to develop improved versions of COVID-19 vaccines that are effective against the SARS-CoV-2 variants of concern (VOC) and can confer long-term protection. Considering the need of the hour, scientists from the University of Sydney in Australia have generated a new COVID-19 vaccine CoVac-II and evaluated its effect against COVID-19 strains. The findings from this study are published on the bioRxiv* preprint server while awaiting peer review.

30 Aug 2021

Mild maternal infections can have permanent impacts on offspring immunity

During pregnancy, mild infections in the mother can have permanent and tissue-specific impacts on offspring immunity, according to a new study in mice.

27 Aug 2021

Could soluble CD24 offer some hope against severe COVID-19?

A recent randomized phase III trial conducted by researchers at the Ohio State University, Columbus, OH, US, evaluated the impact of CD24Fc in severe COVID-19 patients and showed promising clinical efficacy. This study is available as a preprint on the medRxiv* server.

26 Aug 2021

Interleukin 2 News and Research

SARS-CoV-2 can cause sustained biochemical dysregulation that results in long-COVID

Flu shots and COVID-19 immunity

Researchers explore whether cocoa supplementation can reduce aging

Immune-mediated inflammatory disease may increase risk of severe COVID-19 outcomes

Metabolic and immune markers as tools for risk stratification and monitoring in COVID-19

A review of mesenchymal stem cell therapy for severe COVID-19

Cellular program could turn T cells into effective cancer killers

COVID-19 vaccine antibodies inversely related to BMI in obese men, but not women

Activated mast cell disorders potentially linked to SARS-CoV-2 immunity

Implications of persistent SARS-CoV-2 infection in patients with lymphoid malignancies

Research uncovers test to identify iMCD patients with superior response to FDA-approved treatment

Newly discovered cell type makes survivors of sepsis more vulnerable to infections

Implanted cells deliver a biologic drug in response to inflammation in rheumatoid arthritis

Attenuated virulence and protective immunity in SARS-CoV-2 with a mutation in the S1/S2 cleavage site

DNMT2/TRDMT1 gene knockout may potentiate adverse effects related to drug-induced senescence

The impact of mild SARS-CoV-2 infection on maternal-fetal immunity

Polymeric and lipid nanoparticles in self-amplifying RNA vaccines result in higher protein expression and immunogenicity

Next-gen COVID vaccine to make persistent neutralizing antibodies

Mild maternal infections can have permanent impacts on offspring immunity

Could soluble CD24 offer some hope against severe COVID-19?

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News